BioRestorative Therapies: Nasdaq Delinquency Notice for Late 10-Q

What Happened

• BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced on August 21, 2026 that Nasdaq’s Listing Qualifications Department sent a delinquency notice because the company did not timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, in violation of Nasdaq Listing Rule 5250(c)(1). The notice does not immediately affect trading; the company’s common stock continues to trade on the Nasdaq Capital Market under the symbol BRTX. The company says it is working to complete and file the Form 10-Q and will submit a plan to regain compliance.

Key Details

• Notice date: August 21, 2026 (delinquency letter from Nasdaq).
• Form 10-Q period: quarter ended June 30, 2026 (untimely filed).
• Compliance plan deadline: October 20, 2026 to submit a plan to Nasdaq.
• Possible extension: if Nasdaq accepts the plan, the company may receive up to 180 days from the Form 10-Q due date—potentially until February 16, 2027—to regain compliance.
• If Nasdaq rejects the plan, the company can appeal to a Nasdaq Hearings Panel; delisting remains a possible outcome if compliance is not achieved.

Why It Matters

• For investors, the filing highlights a short-term regulatory risk: continued noncompliance could lead to delisting, which would hurt liquidity and could affect the stock’s price and investor access.
• There is no immediate trading suspension, but the company must act by the October 20 deadline (or seek an extension) to avoid further action.
• The company’s next steps—filing the overdue Form 10-Q and securing Nasdaq’s acceptance of a compliance plan—will be material events to monitor.